JAKARTA - A panel of South Korean medical experts announced the COVID-19 vaccine, alerting Moderna to efficacy and safety, and recommending its use Friday, May 21.
In a double-digit review of two Moderna vaccine-fighting dosing regimens, a panel of experts concluded the vaccine was eligible for all adults.
Moderna Vaccine became the fourth COVID-19 vaccine approved by South Korea's Ministry of Food and Drug Safety, after previously alerting AstraZeneca, Pfizer, and Johnson &Johnson vaccines.
The ministry said Moderna's two full-dose regimens show efficacy among all adults. The review was conducted by a panel of clinical trials on 28,207 participants, according to the Korea Times on Friday, May 21.
Data shows that the vaccine has 94.1 percent efficacy in preventing COVID-19, and more than 86 percent in those regardless of age or underlying disease.
The South Korean government is known to have signed a contract with Moderna to supply the COVID-19 vaccine to 20 million people. A targeted dose number arrives before June.
With this agreement, news Samsung Biologics, Samsung Group's biopharmaceutical unit to produce the Moderna vaccine in South Korea in August, is increasingly blowing fast.
SEE ALSO:
Several local newspapers reported, Samsung Biologics almost signed a contract manufacturing organization contract (CMO), to produce the mRNA Moderna vaccine at the plant in Songdo, about 50 km southwest of Seoul.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
